ArticleACS applied bio materials2026
Near-Infrared Fluorescence Imaging and Photothermal Therapy of Tumors Using a Targeted Helical Protein Scaffold.
Article in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Photothermal therapy (PTT) using near-infrared (NIR) photoactive agents offers a minimally invasive approach for tumor ablation; however, many existing platforms rely on polymeric or nanoparticle carriers that limit targeting precision and control over dye loading. Here, we report the design of a modular eight-helix protein scaffold containing 20 cysteine residues that enables covalent, site-specific conjugation of the NIR dye AQuora800-maleimide. The protein scaffold is expressed with different HER2-targeting ligands, and in vitro screening identifies an affibody dimer-based construct (AD-20AQ) as the most effective platform for targeted fluorescent imaging and therapy. In vivo pharmacokinetic imaging studies in a 4T1 murine tumor model reveal enhanced tumor accumulation of AD-20AQ compared to a monolabeled affibody dimer (AD-1AQ), with sustained retention in HER2-positive tumors. Furthermore, PTT of HER2 tumors with an 808 nm laser, following intravenous administration of AD-20AQ, leads to complete tumor ablation. Collectively, these results establish targeted, labeled protein scaffolds as a versatile platform for NIR fluorescence imaging and photothermal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.